

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Serial No.:

10/076,937

Filing Date:

02/15/2002

Applicants:

Dean, Herbert M. et al

Title:

DOSAGE UNIT FOR CARDIOPROTECTION

Atty. Docket No.:

dean0202con

Art Unit:

1617

Examiner:

Hui, San-ming R.

Commissioner for Patents Washington, DC 20231

Dear Sir:

Enclosed for filling in the above-referenced patent application please find an Amendment and Request for Reconsideration, a Fee Transmittal, a check in the amount of \$84.00 and a return postcard.

Respectfully submitted,

Dated: 10/29/02

Robert R. Deleault, Reg. No. 39,165

RECEIVED

NOV 1 4 2002

TECH CENTER 1600/2900

Attorney for Applicant

41 Brook Street

Manchester, NH 03104

Tel. (603) 668-1971

## **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on:

Robert R Ddeautt Robert R Ddeautt

PTO/SB/17 (11-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# **FEE TRANSMITTAL** for FY 2002

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

**TOTAL AMOUNT OF PAYMENT** 

\$)	84.00
Ψ,	07.00

Compl te if Known				
Application Number	10/176,937	<u> </u>		
Filing Date	02/15/2002	· · · · ·		
First Named Inventor	Dean, Herbert M. et al.			
Examiner Name	San-ming R. Hui			
Group Art Unit	1617			
Attorney Docket No.	dean0202con			

METHOD OF PAYMENT (check all that apply)			FEE CALCULATION (continued)						
Check Credit card Money Other None			3. ADDITIONAL FEES						
Deposit Account:			Large Entity Small Entity						
Deposit				Fee Cod	Fee e (\$)	Fee Cod	Fee e (\$)	Fee Description	Fee Paid
Account Number	<del> </del>	<del></del>		105	130	205	65	Surcharge - late filing fee or oath	
Deposit Account				127	50	227	25	Surcharge - late provisional filing fee or	
Name	·			'-'	50		20	cover sheet	
	oner is authori s) indicated belo	ized to: (check all i	hat apply) any overpayments	139	130	139	130	Non-English specification	
	•	_	arry overpayments ncy of this application	147	2,520	147	2,520	For filing a request for ex parte reexamination	
	,	ow, except for the	• ,.	112	920°	112	920*	Requesting publication of SIR prior to Examiner action	
_	entified deposit	•		113	1,840*	113	1 840*	Requesting publication of SIR after	
	FEE CA	ALCULATION			.,010	"	.,010	Examiner action	
1. BASIC FI	LING FEE			115	110	215	55	Extension for reply within first month	
Large Entity				116	400	216	200	Extension for reply within second month	<del></del>
Fee Fee Code (\$)	Fee Fee Code (\$)	Fee Description	Fee Paid	117	920	217	460	Extension for reply within third month	
101 740	201 370	Utility filing fee			1,440	218	720	Extension for reply within fourth month	
106 330	206 165	Design filing fee			•		980	Extension for reply within fifth month	
107 510	207 255	Plant filing fee		119	320	219	160	Notice of Appeal	
108 740	208 370	Reissue filing fee		120	320	220	160	Filing a brief in support of an appeal	
114 160	214 80	Provisional filing	ee	121	280	221	140	Request for oral hearing	
	s	SUBTOTAL (1)	(\$)		1,510	1	1,510	Petition to institute a public use proceeding	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE		140	110	240	55	Petition to revive - unavoidable			
Z. EXTRA C		F	ee from		1,280	241	640	Petition to revive - unintentional	
Total Claims	12 -20**		S9 = Fee Paid	142	1,280 460		640 230	Utility issue fee (or reissue)  Design issue fee	
Independent	5 - 3**		\$42 = 84.00	144	620	244	310	Plant issue fee	
Claims Multiple Depen	- ب			122	130	122	130	Petitions to the Commissioner	
, , , , , , ,				123	50	123	50	Processing fee under 37 CFR 1.17(q)	
Large Entity	Small Entity			126	180	126	180	Submission of Information Disclosure Stmt	
Fee Fee Code (\$)	Fee Fee Code (\$)	Fee Description	<u>ən</u>	581	40	581	40	Recording each patent assignment per	
103 18	203 9	Claims in excess	of 20	· ~ ·	40	361	40	property (times number of properties)	
102 84	202 42	Independent clair	ms in excess of 3	146	740	246	370	Filing a submission after final rejection	
104 280	204 140	Multiple depende	ent claim, if not paid	149	740	249	370	(37 CFR § 1.129(a))	
109 84	209 42	** Reissue indep over original pa		""	140	245	3/0	For each additional invention to be examined (37 CFR § 1.129(b))	
110 18	210 9		s in excess of 20	179	740	279	370	Request for Continued Examination (RCE)	
,		and over origin	·	169	900	169	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$) 84.00			Other fee (specify)						
**or number	r previously paid	i, if greater; For Re	issues, see above	*Red	uced by	y Basi	ic Filing	Fee Paid SUBTOTAL (3)	

SUBMITTED BY				Complete (if applicable)		
Name (Print/Type)	Robert R. Deleault	Registration No. (Attorney/Agent)	39165	Telephone	603-668-1971	
Signature	Rhuellen				10/28/02	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:

10/076,937

Filing Date:

02/15/2002

Applicants:

Dean, Herbert M. et al

Title:

DOSAGE UNIT FOR CARDIOPROTECTION

Atty. Docket No.:

dean0202con

Art Unit:

1617

Examiner:

Hui, San-ming R.

RECEIVED

NOV 1 4 2002

TECH CENTER 1600/2900

Paper No. 7

112100

## AMENDMENT AND REQUEST FOR RECONSIDERATION **PURSUANT TO 37 C.F.R. § 1.111**

**Commissioner for Patents** Washington, D.C. 20231

Dear Sir:

In response to the Office communication mailed July 30, 2002, rejecting Claims 1-10 of the above-identified Application, Applicants respectfully request that the following amendments be entered.

#### IN THE CLAIMS:

Please add the following new Claims.

B 1

- 17. A cholesterol lowering and beta-adrenergic blocking medicament dosage unit comprising a beta-adrenergic blacker and a cholesterol lowering agent that is a statin, said blocker and said agent being combined as a single oral formulation.
- A cholesterol lowering and beta-adrenergic blocking medicament dosage unit consisting of a beta-adrenergic blocker and a cholesterol lowering agent that is a statin, said blocker and said agent being combined as a single oral formulation.

11/13/2002 SZEWDIE1 00000092 10076937